In the latest episode of the PharmaSource podcast, Ben Locwin , Chief Scientist at Black Diamond Networks, explains that GLP-1 drugs represent a significant breakthrough in the treatment of obesity and diabetes and the unintended consequences they are bringing to the industry
Read PA, Khan FZ, Heck PM, Hoole SP, Dutka DP: DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease / CLINICAL PERSPECTIVE
Information about GLP-1 receptor agonist availability has also been updated
0.5 mg of semaglutide equals 5 units in all standard injectable formulations, including PlexusDx compounded options
Market Dynamics: The price of Tirzepatide can also be influenced by broader market factors, such as demand and the availability of similar medications
With limited quality evidence available thus far, the association of GLP-1RAs with the development of DR remains somewhat unclear